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A COMPUTATIONAL MODEL FOR TRANSDERMAL DIFFUSION 
OF LIDOCAINE AND TETRACAINE TOPICAL PATCHES 
By 
Qian Dong 
In recent years, transdermal drug delivery patches (TDDP) have developed rapidly. This is 
because the TDD system has more advantages than traditional drug delivery systems such 
as oral medicine and intravenous injection. In order to reach the circulatory system of the 
human body, drug molecules have to pass through the epidermis (outer layer) of the skin. 
The barrier properties of epidermis originate from low permeability of stratum corneum 
(SC) which is the outermost layer of the human skin. The objective of this thesis is to build 
a Finite Element (FE) model, utilizing commercial FE software (ANSYS), that can be 
implemented to estimate parameters of diffusion as well as common diffusion cell 
experiments. Use of the regular geometry, “brick and mortar”, to simulate tortuous 
intercellular route of SC is presented. It is assumed that diffusion occurs only within the 
SC lipids and the lipids are isotropic. The steady-state flux and lag time are solved and 
compared with the analytical results. 
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The transdermal drug delivery (TDD) system represents a new method to replace oral 
delivery of drugs and hypodermic injection. Although the TDD system is not a perfect 
alternative to traditional drug delivery methods (oral delivery or hypodermic injection), it 
has made an important contribution to medical practice. For thousands of years, people 
have already placed substances on the human skin for therapeutic effects such as traditional 
Chinese medicated bath [2], and, in the modern era, a variety of topical patches have been 
developed to treat chronic diseases. In ancient China, transdermal drug delivery system has 
been one of the ways for external treatment. Treatment of a variety of diseases includes 
dermatosis, rheumatism, joint pain, and others. The drug administered directly to the lesion 
site has less toxic side effects. In the modern era, the first transdermal system for systemic 
delivery consisted of a three-day patch that delivered scopolamine to treat motion sickness, 
and was approved for use in the United States in 1979. A decade later, nicotine patches 
became the first transdermal blockbuster, which raised the profile of transdermal delivery 
systems in medicine, in particular and for the public in general. With the development of 
transdermal drug delivery systems, TDD has already been developed for three generations 
[1-4]. Between 1979 and 2007, numerous transdermal drugs have been approved by the 
2 
FDA each year (Figure 1.1). 
 
Figure 1.1 Cumulative number of transdermal drugs approved by the FDA since 1979. 
Source: The FDA Orange Book. 
  Currently, in an effort to advance TDD systems, transdermal drug delivery patches 
(TDDP) are being mainly fabricated. The nicotine patches have been mentioned widely in 
the literature [4-6], but it is important to notice that these are typical first generation 
transdermal patches with choice of special drugs. The use of TDDP significantly reduces 
major drawbacks that are associated with oral medicine, intravenous injection and 
intramuscular injection, such as viscera stimulation from oral medicine or increasing 
infection risk by injection. It reduces pain and inflammation while propagating quicker 
regeneration of tissues; and also it can avoid high percentage of protein related medicines 
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that can be influenced by the digestive system; moreover, unlike intravenous injection, 
optimal transdermal systems can slowly release medicine in the form of particles to the 
blood stream so as to avoid many undesired side effects. 
  Aside from these comparisons, the TDD still faces a big barrier of human skin. 
Thus, this study focuses on the use of commercial finite element analysis (FEA) software, 
ANSYS, to build a computational model for predicting diffusion in transdermal drug 
delivery patches. The FE results, which are much more conventional, are predicted by 
changing few parameters in the FEA model. This computational model can help the TDDP 
designers to choose ideal parameters for transdermal drug delivery experiments so that 
precious time and expense can be saved from performing long time experiments.   
1.2 Background Information 
1.2.1 Skin Structure  
The skin is a remarkable organ of the body which is able to perform various functions. Skin 
is not only a protective barrier against mechanical, thermal and physical injury and 
potential exposure to hazardous substances, but also has many other functions such as 
absorption, permeability, secretion, excretion and immunity. 
  The skin is a variably lamellar structure, which not only includes three main 
components, epidermis, dermis and subcutaneous layer, but also includes several sub-
structure at three main components as shown in Figure (1.2). Skin is constantly being 
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regenerated by new cell fission from the bottom layer of the skin to the top layer, because 
the bottom layers have the blood supply. The main function of epidermis is to form a tough 
barrier against the outside world, which has the primary obstacle to transdermal drug 
delivery. The dermis is the middle layer of the skin located between the epidermis and the 
subcutaneous layer, which is responsible for the structural integrity of the human skin. The 
subcutaneous layer includes numerous fat cells for isolating cold and trauma from outside 
to the underlying layer.  
Figure 1.2 The structure of human skin which includes three main parts – epidermis, 
dermis and subcutaneous layer. In each layer, they have different low-level structure. 
Source: Falcone, R., Jaffe, M., Ravindra, N.M., New screening methodology for selection of polymeric 
matrices for transdermal drug delivery devices, Bioinspired, Biomimetic and Nanobiomaterials, Volume 2 
Issue BBN2, p. 65-75, 2013. 
1.2.1.1 Components of Epidermis The epidermis is the outermost layers of the human 
skin [8]. The epidermis has 5 low-level layers which have different cell arrangement and 
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components. Figure 1.3 shows different cell arrangement in the epidermis layers. (1) 
Stratum basal is the bottom layer of epidermis. The cells in this layer can constantly 
reproduce so as to get constantly pushed up into the next layer. (2) Stratum spinosum layer 
can prevent bacteria from entering the cells and the moisture being lost. The cells of this 
layer can also reproduce. (3) Stratum granulosum can produce a protein, keratin, which is 
found in nail and hair. The cells, in this layer, cannot reproduce themselves. (4) Stratum 
lucidum layer plays the role of cushioning and protection and is found only on the palms 
of hands and soles of feet. (5) Stratum corneum is the outer-layer of skin which forms the 
primary barrier to drug transport.  
 
Figure 1.3 shows the schematic image of the epidermis with its sub structure such as the 
stratum basale layer, the stratum spinosum layer, the stratum granulosum layer, the stratum 
lucidum layer and the stratum corneum layer. The stratum corneum layer directly contacts 
with external environment.  
Source: Marks, J.G., Miller, J., Lookingbill and Marks' Principles of Dermatology (4th ed.), Elsevier, p. 1–
7. ISBN 1-4160-3185-5, 2006. 
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1.2.1.2 Stratum Corneum (SC) The outer 10-15 micrometer of skin, called stratum 
corneum, is a dead tissue that forms primary barrier to drug transport, since stratum 
corneum is a composite material made of protein and lipids structurally organized as “brick 
and mortar”, as shown in Figure 1.3. The hydrophobic lipid bi-layers fill all of extracellular 
spaces, where this lipid-enriched matrix is organized into lamellar membranes that 
surround the corneocytes. The lipid-enriched matrix of the stratum corneum includes not 
only the structure that limits transdermal delivery of hydrophobic drug, but also the so-
called stratum corneum “reservoir”, within which lipid soluble drugs, such as topical 
corticosteroids, can accumulate and be slowly released [6]. Therefore, once hydrophobic 
medicine can successfully pass through stratum corneum, they get into the viable epidermis 
layer which has live cells and nerves but not vessels; it can diffuse rapidly through deeper 
tissue and be taken up by the underlying capillaries for systemic administration [10].  
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Figure 1.4 The SC layer consists by corneocytes which are like scaffold for SC structure, 
and extracellular hydrophobic matrix.  
Source: Sebastien Henry, D., V.M., Mark, G.A. and Mark, R.P., Microfibricated Microneedles: A Novel 
Approach to Transdermal Drug Delivery, Journal of Pharmaceutical Sciences, Vol. 87, No. 8, August 1998. 
  Although the corneocytes (Figure 1.4) contribute volume to be a scaffold for the 
stratum corneum structure, modern transdermal delivery strategies focus primarily on 
manipulations of the extracellular lipid milieu. The reason why hydrophilic drugs have 
exceptional low permeability to cross stratum corneum is the consequence of several 
characteristics of the lipid-enriched, extracellular matrix, including its organization into a 
highly complicated and tortuous diffusion pathway, such as mortar between bricks, 
imposed by geometrically arrayed corneocyte “spacers” [6]. Furthermore, not only the 
stranger pathway of bilayers’ extracellular lipids, but also the three extreme hydrophobic 
components, ceramide fatty acid and cholesterol, of lipid contribute to the barrier function, 
as shown in Figure 1.5. 
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Figure 1.5 The structure of the major components of the stratum corneum intercellular 
lipids. Numbers 1 to 8 are ceramides and represent a thin layer with chromatographic 
mobility, with ceramide 1 being the least polar and ceramide 8, the most polar. The letters 
in square brackets are the structural classifications of the ceramide as suggested by Motta 
et al.  
Source: Biochim Biophys Acta 1993;1182: 145-51.  
1.2.2 Transdermal Patches  
Transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a 
specific dose of medication through the skin and into the bloodstream. An advantage of 
transdermal patch over other types of delivery of medication is that the patch provides a 
controlled release of the medication into the patient. The main disadvantage to transdermal 
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delivery systems stems from the fact that the skin is a very effective barrier; as a result, 
only medications whose molecules are small enough to penetrate the skin can be delivered 
by this method. Nowadays, there are three main generations of transdermal drug delivery 
systems. The first generation is a very simple patch which has specific medicinal properties 
such as low-molecular weight, lipophilic and efficacious at low doses. Base on Fick’s law, 
the driving force of first generation TDD system is only the concentration gradient. The 
second generation of transdermal delivery systems already consider that skin permeability 
enhancement is needed to expand the scope of transdermal drugs. Thus the second 
generation of transdermal delivery systems add an enhancer layer to increase the skin 
permeability by reversibly disrupting stratum corneum structure or simply adding more 
driving force for transport into the skin such as chemical disruption, iontophoresis and non-
cavitational ultrasound. The third generation transdermal delivery systems is poised to 
make significant impact on drug delivery because it targets its effects to the stratum 
corneum [5]. This targeting enables stronger disruption of stratum corneum layer of skin, 
while still protecting the deep tissue. For example, the micro-needles are conceptually a 
straightforward way to directly penetrate the stratum corneum layer.  
  Normally, transdermal patches have similar structures. There are four basic layers 
for the common transdermal patches as shown in Figure 1.6. Clear backing layer isolates 
other layers from contacting with natural environment. Drug reservoir layer stores the 
medicinal particles. Drug delivery membrane layer controls the ratio of drug actives in the 
10 
form medicinal particles. Contact adhesive layer directly attaches to the skin. Based on 
different patches, which have different enhancers to increase the diffusion of medicine into 
the skin, different layer for enhancers are added. In this study, the author uses SYNERA 
Lidocaine and Tetracaine topical patches. These patches have extra integrated heating 
component layer for increasing drug diffusion rate by additional temperature gradient, 
which can heat the patch and skin surface to 42 ° C at room temperature. Therefore, the 
SYNERA patch has an additional enhancer layer between the clear backing layer and the 
drug reservoir.  
 
Figure 1.6 Common transdermal patch structure which includes four basic layers such as 
(i) clear backing layer, (ii) drug reservoir layer, (iii) drug-release membrane layer and (iv) 
contact adhesive layer.  
Source:(http://drugdelivery.chbe.gatech.edu/Papers/2012/Prausnitz%20Derm%20Book%20Chapter%20201
2.pdf) Accessed on March 15, 2016. 
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1.2.3 ADME/T Mechanism 
ADME/T mechanism is abbreviation in pharmacokinetic and pharmacology for absorption, 
distribution, metabolism, excretion and toxicity, and describes the disposition of a 
pharmaceutical compound within an organism. The five criteria already describe all 
influences when particles of drug/drug actives touch and interact with human tissues. 
Nowadays, although drug designers can synthesize many different kinds of drugs which 
have different chemical components, 95% of them cannot be directly used in clinical trials, 
because of insufficient ADME/T properties. 
1.2.3.1 Toxicity Arguably, drug toxicity is the most challenging drug property that 
remains one of the most significant reasons for many drugs failing to reach the market and 
for many drugs not approved to the market and withdrawal from the market during the late-
stage of drug development [12]. Base on individual differences, drug toxicity may occur 
from any sources inside the human body such as receptor or enzyme and DNA interaction. 
In this study, the anesthetic agents, Lidocaine and Tetracaine, are high lipophilic particles 
whose concentrations need to be controlled below specific number in blood.  
1.2.3.2 Excretion Drug excretion is the process whereby a drug molecule is eliminated 
by human organs such as liver and kidney. Base on blood flow, protein binding and 
lipophilicity, scientists can roughly predict passive excretion [13]. For example, there is 
enzyme which can hydrolyze the Tetracaine in the circulatory system. But the renal 
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excretion process is more complex due to more than few processes of excretion.  
1.2.3.3 Metabolism Compounds begin to break down as soon as they enter the human 
body by some enzymes in the liver. As metabolism occurs, the initial (parent) compound 
is converted to new compounds called metabolites; and also metabolism can deactivate the 
administered dose of parent drug and this usually reduces the effects on the body; moreover, 
metabolism may also be pharmacologically active. 
1.2.3.4 Distribution Distribution is a transport process by bloodstream which is the main 
circulatory system in the human body. Bloodstream delivers drug molecules from areas of 
higher concentration to areas of lower concentration. Some factors affecting drug 
distribution include regional blood flow rates, drug molecular size, polarity and binding to 
serum proteins, forming complex. Sometimes, distribution will face some serious barriers 
such as blood brain-barrier.  
1.2.3.5 Absorption For a compound to reach a tissue, it usually must be taken into the 
bloodstream before being taken up by the target cell. In this study, drug particles/actives 
should pass through the stratum corneum layer so as to be taken up into systemic circulation. 
Different drug delivery systems have different mucous membranes which also have 
different absorption mechanism. Thus, for this study of transdermal drug delivery, the 
author will discuss percutaneous absorption.  
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1.2.4 Percutaneous Absorption Mechanism  
Percutaneous absorption includes entire procedures of drugs delivery from the outermost 
layer of the skin to the systemic circulation. This process requires penetration into the 
layers of the skin with subsequent permeation across each layer of the skin and finally 
uptake to the capillary blood vessel in the upper region of the dermis [13]. In the 
percutaneous absorption system, different skin structure will give different routes for drug 
passives to diffuse into blood capillary. Thus, processes of passive diffusion of drug 
molecules are elaborated in the following model - Figure 1.7.  
 
Figure 1.7 shows that before drug molecules reach systemic circulation, drug molecules 
first face partition phenomenon of the skin followed by diffusion through the epidermis 
layer.     
Source: Alan, B., Ursula, G.R., Pierre, K., Panos, M. Olavi, P., In silico prediction of ADME and 
pharmacokinetics, European Journal of Pharmaceutical Sciences, 17, pp. 183-193, 2002. 
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1.2.4.1 Routes of Penetration Absorption via the transdermal route primarily occurs 
by passive diffusion through the SC. The rate of diffusion depends on several properties 
such as: (1) diffusivity between drug molecules and the SC layer, applied concentration of 
drug, surface area of the skin exposed to the drug molecules and the length of diffusion 
pathway. Except for the same procedures as shown in Figure 1.7, there are two main routes: 
the trans-epidermal route and the trans-follicular route, to penetrate the SC layer. In the 
early time periods, chemical particles can penetrate the SC via skin appendages such as 
hair follicles, sebaceous glands or sweat glands with absorption through the squamous 
epithelial cell lining these structures into the deeper layers of the skin (Figure 1.8). 
However, due to large surface areas, trans-epidermal diffusion gradually increases until 
dominating penetration processes.  
  As shown in Figure 1.8, there are two other sub-pathways for the trans-epidermal 
route. The first, the transcellular is the diffusion pathway across corneocytes. The second, 
the intercellular contributes a tortuous pathway between corneocytes for lipophilic 
molecules. Hence, the permeability of the SC components, lipid protein matrix and 
corneocytes, are the most important properties of transdermal delivery systems. In this 
study, the anesthetic agents, Lidocaine and Tetracaine, are highly lipophilic. The 
octanol/water partition ratio (Kow) of Tetracaine reaches 5370 at pH 7.3; and Kow of 
Lidocaine also reaches 182 at pH 7.3. Based on the partition ratio, this study only focuses 
on intercellular pathway for anesthetic agent transport. Geometric structure of the 
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intercellular pathway is demonstrated in Figure 1.8.  
 
Figure 1.8 demonstrates two penetration routes for percutaneous absorption. (1) The trans-
appendageal route dominates early when drug particles are put on the skin surface. (2) The 
trans-epidermal will gradually dominate instead of the trans-appendageal route.   
Source: Alan, B., Ursula, G.R., Pierre, K., Panos, M. Olavi, P., In silico prediction of ADME and 
pharmacokinetics, European Journal of Pharmaceutical Sciences, 17, pp. 183-193, 2002. 
1.2.4.2 Factors Affecting Drug Permeation The stratum corneum layer and other 
epidermal layers are quite distinct structures [14]. Considering drug diffusion through 
epidermis, the drug solution must balance between lipid solubility and aqueous solubility 
to handle variable structures of the epidermis. The structure of the SC, brick and mortar, 
essentially provides a lipophilic milieu for drug transport whereas the other layers of 
epidermis provides a more hydrophilic domain. Therefore, the drug molecules which are 
balanced between lipid and water solubility can successfully reach systemic circulation 
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without excess partition in different solubility media. Based on partition character, the Potts 
& Guy equation (Equation 1.1) describes an empirical equation governing highly lipophilic 
compounds which use intercellular pathway to penetrate the SC barrier. Equation (1.1) 
shows that the permeability of highly lipophilic compounds mainly relate to the partition 
coefficient and molecular weight. Also, Table 1.1 demonstrates that additional factors will 
affect the permeability of diffusants.    
     log k = 0.71log Kow − 0.0061𝑀𝑊 − 2.74    (1.1) 
k is the permeability of the diffusant (m/s).  
Kow is the partition coefficient of the diffusant.  
MW is the molecular weight of the diffusant (g/mol). 
Table 1.1 Factors Affecting Drug Permeation 
(a) Variations in skin structure 
(b) Sites of application 
(c) Hair follicles ( effects of hair or shaving the site of application) 
(d) Sweat glands 
(e) Effect of age, blood supply, body temperature and composition (e.g. elevated 
body temperature, hyperthyroidism & inflammation etc.) 
(f) First pass metabolism by the skin 
(g) Ability of the skin to act as a reservoir for transdermal agents 
(h) Physicochemical characteristics of the transdermal agents (the ideal 
compounds are low molecular weight, lipophilic, soluble in oil & water and have 
a high partition coefficient and melting point) 
(i) Drug stability 
(j) Use of solvent carriers or vehicles 
(k) Use of penetration enhancers ( nature & type) 
(l) Use of delivery devices etc. 
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1.2.5 Diffusion 
Diffusion refers to the process by which molecules intermingle as a result of their kinetic 
energy (In physics, the kinetic energy of an object is the energy that it possesses due to 
motion.) due to random motion. Therefore, the diffusion motion does not come from any 
outside force, but more as result of the random distribution of atoms being mixed. By 
definition, the atomic motion due to diffusion is random. However, a selective diffusion 
process, called osmosis, is driven by the internal energy of the solvent molecule so that the 
random diffusion has direction of molecule movement. This internal energy based driving 
force is the result from different gradients such as differences in concentration, temperature 
or magnetic field. This process was originally evaluated by Adolf Fick in the 19th century 
[15], who described this phenomenon by equation (1.2). There are two simple descriptions 
of Fick’s law (Table 1.2). 
Table 1.2 Description of Fick's Law 
1, The molar flux due to diffusion is proportional to the concentration gradient. 
2, The rate of change of concentration at a point in space is proportional to the second 
derivative of the concentration with space. 
1.2.5.1 Fick’s Laws of Diffusion The most common mathematical form of Fick’s laws of 
diffusion makes the following assumptions: (i) The receptor phase is a perfect sink. (ii) 
Depletion of the donor phase is negligible. (iii) The membrane is homogenous. 
        𝐽𝑖 = −𝐷𝑖∇𝐶𝑖          (1.2) 
The Ji is the molar flux (mol m
2s-1) and the Di is the diffusion coefficient (m2s-1). 
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  The negative sign of equation (1.2) means that the transport direction of species i 
is reversed with concentration gradient, from higher concentration to lower concentration; 
moreover, the sign ∇ Ci means the gradient of difference of concentration with distance. 
         ∇𝐶𝑖 =
𝜕𝐶𝑖
𝜕𝑥
        (1.3) 
From the continuity equation for mass: 
         
𝜕𝐶𝑖
𝜕𝑡
+ ∇C𝑖 = 0       (1.4) 
We can derive the Fick’s second law directly: 
         
𝜕𝐶𝑖
𝜕𝑡
= 𝐷𝑖∇2𝐶𝑖       (1.5) 
  Equation 1.4 shows a linear equation for the Fick’s second law. Therefore, if this 
assumes that 𝐷𝑖 is a constant, the relationship between diffusion concentration and time 
can be calculated from the Fick’s second law. However, this assumption is only true in the 
dilute solution. 
1.2.6 Diffusion Coefficient Prediction Theory 
In the above sections, diffusion processes and modern mathematical equations, Fick’s laws 
are introduced. In each equation of mass diffusion processes, the diffusion coefficient is 
the most important parameter. Therefore, understanding how to calculate the diffusion 
coefficient is very important for solving mass diffusion problems [16] [17].  
1.2.6.1 Solid Media The diffusion coefficient in solids, at different temperatures, is 
generally found to be well predicted by the Arrhenius equation:  
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𝐷 = 𝐷0𝑒
−𝐸𝐴/(𝑘𝑇)                      (1.6) 
where 
𝐷 is the diffusion coefficient (m2/s).  
𝐷0 is the maximum diffusion coefficient (at infinite temperature; m
2/s). 
𝐸𝐴 is the activation energy for diffusion in dimensions of (J atom
-1).  
T is the absolute temperature (K). 
k is the Boltzmann constant.   
1.2.6.2 Liquid Media The diffusion coefficient, as function of temperature, in liquids 









                        (1.7) 
D is the diffusion coefficient (cm2/s). 
T is the absolute temperature (K). 
T1 and T2 denote temperatures T1 and T2, respectively. 
μ is the dynamic viscosity of the solvent (Pa·s). 
1.2.6.3 Gas Media The dependence of the diffusion coefficient on temperature for gases 





                  (1.8) 
D is the diffusion coefficient, which is expressed in cm2/s. 
1 and 2 index the two kinds of molecules present in the gaseous mixture. 
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T is the absolute temperature (K). 
M is the molar mass (g/mol). 
p is the pressure (atm). 
 is the average collision diameter (the values are tabulated) (Å). 
Ω is a temperature-dependent collision integral (the values are tabulated but usually ~ 1) 
(dimensionless). 
1.2.6.4 Free Volume Theory In percutaneous drug delivery, if only the intercellular 
pathway is considered, the drug molecules will migrate through the extracellular matrix of 
the epidermal layer for reaching bloodstream or nerve cells located at the dermis layer. The 
extracellular matrix is composed of macromolecular polymers such as proteins. Therefore, 
the diffusion of drug molecules can be considered as mobility of small molecules in the 
macromolecular matrix. Base on Equation (1.6), the mobility is considerably influenced by 
temperature and concentration. However, the extracellular matrix is not common solid 
media which can directly use Equation (1.6) for the determination of the diffusion 
coefficient. In 1959, Cohen and Turnbull originally suggested an assumption [18] that there 
were empty space, called free volume, between molecular sequences, which can be 
migration pathways for small hard sphere molecules. In transdermal delivery systems, there 
are many factors which will affect the mobility of the drug molecules. However, for 
simplifying this case, only free volume concept need to be considered. Therefore, diffusion 
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coefficient can be assumed to be proportional to the probability of locating a vacancy of 
volume V* or larger and could be written [7]. 
         𝐷 = A 𝑒
𝛾𝑉∗
𝑉          (1.9) 
V* is the critical volume for migrating molecule. 
γ is the overlap factor of free volume. 
A is the defined constant which is associated with kinetic energy. 
V is the specific volume.  
  Although, Equation (1.9) already suggests a mathematical method for mobility 
based on free volume theory, this is not enough for dealing with problems of drug diffusion 
through the skin. Therefore, Vrentas and Duda [19] introduced the following relationship 
between more diffusion units and free volume: 







        (1.10) 
VFH is the average hole of free volume. 
w1 and w2 represent species 1 and 2.  
M1j and M2j are diffusion units.  
  The above equations clearly indicate that the diffusion coefficient of small 
molecules is an exponential function related to free volume; and also the free volume is 
related with molecular shape and size. However, Vrentas and Duda [19] further simplified 
Equation (1.9) such as the Equation (1.11). 
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𝑉        (1.11) 
D is diffusion coefficient. 
D0 is the pre-exponential factor.  
E is the attraction energy between the molecules.  
K and T are the Boltzmann’s constant and absolute temperature.  
ξ is the ratio of solvent to polymer jumping units.  
V* is the critical space of free volume for molecule jump. 
V is provided by polymer matrix for diffusion.  
  By using Equation (1.10) in Equation (1.11) to obtain Equation (1.12) about 
diffusion of a solute in a polymeric matrix. 






𝑉𝐹𝐻        (1.12) 
Ws and Wp are the weight percentage of drug or polymer matrix. 
Vp and Vs are the embedded volume of matrix and drug.  
VFH is average hole of free volume. 
E is the attraction energy between the molecules.  
K and T are the Boltzmann’s constant and absolute temperature.  
ξ is the ratio of solvent to polymer jumping units.  
  However, a modified equation, in copolymer media, of molecular migration in 
polymer matrix was suggested by Duda and Zelinsky at 1992 [20]. 
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𝑉𝐹𝐻     (1.13) 
V2k (k is for either a or b) is defined as the specific volume of block k in the copolymer at 
0 K; and W2k (k is for either a or b) is defined as the weight fraction of block k in the 
copolymer. When polymer matrix is homo-polymer, W2a is equal to zero and W2b is equal 
to equation 1.12. The Duda-Zelinsky equation reduces to Vrentas-Duda equation.  
1.2.7 Partition Coefficient  
The term, partition coefficient, is the ratio of a compound in a mixture of two immiscible 
phases in equilibrium so as to measure the different solubility of the compound in these 
two phases (Equation 1.14). Kow is the ratio between solution of octanol and water. 




𝑢𝑛−𝑖𝑜𝑛𝑖𝑧𝑒𝑑}     (1.14) 
  In pharmacology, the partition coefficient strongly affects how easily the drug can 
reach its intended target in the body, how strong an effect it will have once it reaches its 
target, and how long it will remain in the body in an active form [20]. Specifically, for a 
drug to be percutaneously absorbed, normally it must first pass through lipid bilayers of 
corneocytes in the outermost layer (SC) of the epidermis. Hence, the Kow of diffusant 




MATERIALS AND METHODS 
2.1 Materials 
The research material, considered in this study, is a commercial topical anesthetics patch, 
SYNERA, which combines amide (lidocaine) and ester (Tetracaine) local anesthetic for 
use on intact skin to provide local dermal analgesia for superficial venous access and 
superficial dermatological procedures such as excision, electrodessication and shave 
biopsy of skin lesion. The structure of SYNERA is shown in Figure 2.1. Table 2.1 presents 
the basic information of SYNERA.  
Figure 2.1 Synera patch not only includes drug reservoir and other common layers of 
transdermal delivery patches, but also includes CHADD heating element layer which uses 
chemical reaction to create extra temperature gradient instead of using drug vehicles for 
drug diffusion enhancement. 
Source: Crank, J., The mathematics of diffusion (2nd Ed.). 2-12, 46-47, 1975. 
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Table 2. 1 Basic Information of SYNERA 
Featured Indication 
Surface anesthetic for minor dermatological procedures in adults and needle punctures 
of the skin in adults and children ≥3 years of age 
Mechanism of Action 
Local anesthetic agent blocks voltage-gated sodium channels 
Dosage and Administration 
Doses per patch 70 mg/70 mg 
Patch size                              8.5cm x 6.0cm 
Drug cover area                         10cm2 
Route of administration                  Dermal (topical application) 
Application site                        Normal intact skin 
Application time                        30 min 
Number of simultaneous     
plasters (adults)              
1–4 (maximum 4 per 24 h) 
Number of simultaneous                 
plasters (children)  
1–2 (maximum 2 per 24 h) 
Mean Peak Plasma Concentration Following Dermal Application for 30 min of Two 
Plasters Simultaneously 
Number of SYNERA Patches 1 
Age Range (yr)                       18- 65 
Application Time (min)                   30 
Drug Content (mg)                       Lidocaine 70 /Tetracaine 70 
Estimated Amount Absorbed (mg)       Lidocaine/Tetracaine 1.7/1.6 
Cmax (ng/mL)                           Lidocaine/ Tetracaine 1.7/0.9 
Most Frequent Treatment-Related Adverse Events of Mild to Moderate Intensity 
in Clinical Trials 
Erythema, oedema, pruritus, burning sensation 
Partition Coefficient of Octanol/Water   
Lidocaine                                
182 at pH 7.3 
Tetracaine                               
5370 at pH 7.3 
Molecular Weight  
Lidocaine                                
234.34 g/mol 
Tetracaine                               
264.363 g/mol 
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  Although two local anesthesia agents, Lidocaine and Tetracaine, are formulated 
by eutectic methods, eutectic mixture is not a crystal but a liquid. This is because the 
melting point of this eutectic mixture is lower than room temperature. Hence, unlike other 
solid forms of anesthetic agents, SYNERA does not need diffusion vehicle for transdermal 
drug delivery in order for it to increase the drug concentration in the drug reservoir layer. 
These two special factors, liquid eutectic mixture and thermal enhancer, remarkably 
increase the drugs’ absorption ability and minimize the action time of patches so as to avoid 
many side effects, such as skin allergy, from drug delivery for long durations.  
2.2 Methods 
2.2.1 Parameters Switching 
In the commercial FEA software, ANSYS 15.0, there is no mass diffusion package. 
Therefore, the author has used thermal analysis package instead of mass diffusion. The 
reasons for this implementation will be explained in the subsection. 
2.2.1.1 Steady-State Diffusion Fick’s first law introduces the theory of diffusion flux, 
J (kg/m2·s), which is the rate of mass concentration transfer through a given surface, 
Equation (1.2), per unit time. Similarly, heat flux or thermal flux, q (J/ m2·s) is the rate of 
heat energy transfer through a given surface, per unit time, Equation (2.1). Comparing 
Equation (1.2) with Equation (2.1), it is easily understood that mass flux and heat flux 
separately relate to concentration or temperature gradient; and also, D and k are the 
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diffusion coefficient of different transfer equations.  
 q = −k
𝑑𝑇
𝑑𝑥
                           (2.1) 
q is the heat flux (J/ m2 s). 
k is the thermal conductivity (J/m·K·s).  
T is absolute temperature (K). 
x is distance of temperature gradient (m).  
2.2.1.1 Transient Diffusion In Fick’s first law, flux is a constant which will not change 
with time; it is called steady- state diffusion. In the same situation, heat flux is also constant. 
However, to reach steady state will require some time. Therefore, Fick’s second law, 
Equation (1.5), was introduced to demonstrate the relationship between time and flux for 
transient diffusion analysis. Also in the heat transfer analysis, there are similar equations 







∇2𝑇                       (2.2) 
k is the thermal conductivity (J/m·K·s).  
T is absolute temperature (K). 
𝜌 is the density (kg/m3). 
𝑐𝑝 is the specific heat capacity (J/(kg·K). 
  Based on the above comparison, except for some differences between parameters, 
the form of the two transfer equations are same. Therefore, the use of heat transfer analysis, 
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instead of mass diffusion analysis, is viable whether steady-state or transient situation. The 
parameter switch is shown in Table 2.2.  




Conductivity Temperature Density 
Heat  
Capacity  









kg/m2·s m2/s kg/m3 1 1 
2.2.2 Finite Element Model  
This study uses 10 layers in the form of brick and mortar geometry to simulate the two-
dimensional (2D) geometry of the SC (Figure 2.2). Element type is 4 nodes of two 
dimension element, PLANE 55, for thermal analysis. Based on Table 2.2, the conductivity 
can be directly replaced by diffusivity (D); and also for transient analysis, specific heat 
capacity (Cp) and density (𝜌) are equal to one; moreover, the initial concentration is equal 
to 70 kg/m3 for each anesthetic agents. For the shape of the finite element model, the lipid 
layer between two corneocytes (S) is equal to 0.1 micrometer; and also the width (d) and 
height (h) of corneocytes are 40 micrometer and 1 micrometer, respectively; moreover, the 
length (ls) of two lipid pathway in y direction is equal to 10 micrometer.  
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Figure 2.2 Geometric Shape of Brick and Mortar Model 
2.2.3 Theoretical Calculations of Diffusion Parameters  
Transdermal diffusion is not totally like simple mass diffusion, such as diffusion of 
hydrogen through metal. This is because, when drug molecules migrate between lipid 
media, molecular distribution should be considered first, which means some molecules will 
dissolve in liquid so that these molecules cannot pass through the SC even with enough 
diffusion time. Hence, the solubility between transfer media and drug will be considered 
(The partition ratio of octanol and water is to estimate distribution phenomenon).  
2.2.3.1 Maximum Flux Determination The steady-state diffusion of a drug across the 
skin may be described by Fick’s first law, Equation (1.2). In this situation, Fick’s first law 
can be manipulated by considering solubility between stratum corneum and drugs [21]. 
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      𝐽𝑚𝑎𝑥 = (
𝐷
ℎ
) ∙ 𝐾𝑠𝑐/𝑣 ∙ 𝐶𝑣,𝑠𝑎𝑡 = 𝑘𝑝 ∙ 𝐶𝑣,𝑠𝑎𝑡    (2.3) 
Jmax (kg/m
2 s) is the maximum drug flux when the system reaches steady- state. D (m2/s) is 
its diffusion coefficient in the stratum corneum (SC). 
KSC/v is the drug's SC-vehicle partition coefficient. 
h is the length of lipid pathway taken by the penetrant through the SC. 
Cv,sat ( kg/m
3) is saturated concentration of the drug in the vehicle. 
kp (m/s) is the permeability of drug molecule (In this study, it can be directly calculated by 
Equation (1.1)).  
  Comparing Equation (2.3) with Fick’s first law, the diffusion coefficient of 
transdermal diffusion is manipulated to DKSC/v. By using permeability (kp) in Equation 
(2.3), the new diffusion coefficient will relate to permeability as in Equation (2.4). The new 
diffusion coefficient Ds will be used for FE model. 
𝐷𝑠 = 𝐾𝑝 ∙ ℎ                          (2.4) 
2.2.3.2 Permeability Determination The author has already described Potts & Guy 
equation, Equation (1.1), for permeability coefficient (kp) of each drug across the skin from 
aqueous solution. For calculating the corrected permeability coefficient (Kpcorr), the 
following Cleek and Bunge Equation (2.5) will be used for highly lipophilic species for 
which viable epidermis can contribute to rate-control [22]. 
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        (2.5) 
  MW is the drug’s molecular weight. Therefore, if the diffusion pathway length (h) 
is calculated as in Figure 2.2, permeability and diffusion coefficient of each drug can be 
calculated. The results are shown at Table 2.3. The diffusion pathway length comes from 
10 layers in the FE model (h=101μm). 
Table 2.3 Diffusion Coefficient of FE Model 
Permeability kp (m/s) 
Lidocaine                                        
8.3E-9(m/s) 
Tetracaine                                     
6.02E-8(m/s) 
Diffusion Coefficient Ds (m2/s) 
Lidocaine                                     
8.383E-13(m2/s) 
Tetracaine                                      
6.08E-12(m2/s) 
2.2.3.3 Lag Time The term of time-lag is the period between closely related events. In 
this study, anesthetic agents, lidocaine and tetracaine, should transfer across the epidermis 
layer so as to reach the nerve cells of the dermis layer. Although, Fick’s first law can be 
used to predict the maximum flux of diffusion, the value of flux always changes with 
diffusion time. This is because the concentration gradient between two sides of a membrane 
is not always constant (Figure 2.3). Based on Figure 2.3, the changing concentration with 
increasing time is not linear before the concentrate penetrates the entire thickness of the 
membrane. Hence, the time of concentration, or flux, required to reach stead state is called 
the lag time (tL) [22]. The lag time for all FE model results are calculated by extrapolation 
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of the steady-state portion of the mass accumulation curve to the time axis. Lag time is 
related to the thickness of the skin, or length of diffusion pathway when geometry of media 
is irregular shape such as twist lipid pathway, and the diffusion coefficient. The equation 
for lag time is described by Equation (2.6). 
         𝑡𝐿 =
ℎ2
6𝐷𝑠
         (2.6) 
 
Figure 2.3 shows the changing processes of the concentration gradient with increasing 
time. Concentration gradient is not linear before concentration reaches the other side of the 
membrane at t3. After t3, the concentration gradient is linearly decreasing. 
2.2.3.4 Effect of Temperature In the experimental transport of drugs through cell 
membrane, the temperature should be strictly controlled since temperature can increase the 
mobility of diffusion molecules. Also the permeability of drug increases significantly as 
the experimental temperature is increased in increments of approximately 7 °C [23]. It is 
observed that the apparent permeability and temperature are related by an exponential 
relationship that conforms to the Arrhenius equation. In this case, the permeability of 
33 




                          (2.7) 
where Papp is the apparent permeability which is from Potts & Guy equation; K is the 
partition coefficient between media and diffusants; h is the length of the pathway. 





                      (2.8) 
  Assuming that the partition coefficient and length of diffusion pathway remain 
constant over the range of temperature studied, the following relationship can be derived 
as in Equation (2.8) [23].  
𝑃𝑎𝑝𝑝 ∝ 𝑒
−1
𝑇                             (2.9) 
  This suggests that the apparent permeability of drugs increases exponentially with 
temperature. A plot of logarithm of apparent permeability versus absolute temperature will 
yield a linear relationship such as in Figure 2.4. In this study, a heating layer is also added 
to topical patches to increase the skin temperature up to 40 °C. Hence, the relationship 
between permeability of drugs, Lidocaine and Tetracaine, and temperature will be plotted.  
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Figure 2.4 A plot of lnP versus 1/T for five different temperatures, viz., 23°C, 30°C, 37°C, 
45°C, and 52°C, were utilized in individual permeation experiments. Four different 
diffusants transfer across porcine buccal mucosa.  
Source: Kulkarni, U.P., Mahalingam, R., Li, X., Pather, I. and Jasti, B., Effect of Experimental Temperature 
on the Permeation of Model Diffusants Across Pocine Buccal Mucosa, AAPS PharmSciTech, Vol. 12, No. 
2, DOI: 10.1208/s12249-011-9624-z, 2011. 
2.2.3.5 Mass Absorbed. The flux and permeability coefficient allow an exposure 
assessment over time in steady-state condition [24]. When Fick’s first law of diffusion is 
applied, Kp is constant over the range of concentration. Therefore, in order to characterize 
the quantity absorbed (M), some risk assessors have to be integrated over Kp by multiplying 
the chemical concentration (C) (i.e. the flux: J = Kp x C), the exposed surface (S) and the 
exposure time (t): 
     dM = J × S × dt = Kp × C × S × dt      (2.10) 
  From Equation (2.9), the amount of absorbed mass increases with increasing 
permeability when the area and diffusion time are assumed to be constant. Hence, the 




  However, in this study, the FE model is only a two dimensional model. Also the 
time-lag should be considered. Therefore, the new equation derived from Equation (2.9) is 
the following. 
        
𝑑𝑀
𝑑𝑆
= 𝐽 × (𝑡 − 𝑡𝐿)       (2.11) 
  When active time is bigger than time-lag (tL), Equation (2.10) can be used for 
prediction of permeation mass. This is because, after tL, the diffusion process is going to 
be steady-state. 
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CHAPTER 3 
RESULTS AND DISCUSSION 
3.1 Maximum Flux and Lag Time 
In steady-state, the maximum flux, Jmax, should be first considered. FE results compared 
with analytical results for flux (Equation (2.4)) and for time lag (Equation (2.6)) are 
presented in Table 3.1. After lag time tL, the diffusion system reaches steady state at the 
same location. For estimating the lag time across ten layers in the FE model, Equation (2.9) 
is used to plot the mass accumulation curve; and also, the ending time of diffusion process 
is 4000s (Figure 3.1) because analytical results of time-lag of lidocaine is 2028s. Hence, 
the processing time of Tetracaine is 500s (Figure 3.2) because analytical lag time is 280s. 
Table 3.1 Analytical and FE Results (Flux and Lag Time) 
 Analytical results FE results 
Lidocaine   
SS Flux (kg/m2 s) 0.581E-6 0.560E-6 
Time lag (s)  2028 2020 
Tetracaine   
SS Flux (kg/m2 s) 4.214E-6 4.07 E-6 




Figure 3.1 shows that the cumulative permeation curve of Lidocaine per unit area has two 
portions. The initial portion of the curve represents non-steady state diffusion, and linear 
portion corresponds to steady state diffusion. Therefore, if extending steady state line 
intersects with time axis, the lag time will be gained. The intersection point is between 
2040s and 2000s.  
 
Figure 3.2 shows cumulative permeation curve of Tetracaine. This curve also has two 
portions, similar to the results for Lidocaine. Extending steady state line intersects with 
time axis to gain the intersection point which is between 275s and 280s. Hence, the FE 
result of lag time when Teracaine passes through ten layer-model is 272.5s.  
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3.2 Concentration Distribution 
The concentration distribution in the lipid layers of the 10 layers stratum corneum model 
is depicted in Figure 3.3 at 1800s. The concentration of Lidocaine (Figure 3.3 (A)) in the 
bottom of the model is not steady state because diffusion time is smaller than lag time (tL= 
2028s). However, Tetracaine (Figure 3.3(B)) is a good approximation for the steady state. 
A path was created at location 101µm with the lipid diffusion pathway and the 
concentration distribution across the SC is shown in Figure 3.4.  
 
 
Figure 3.3 shows the contour plots of concentration distribution. (A) Contour plot of 
concentration distribution of Lidocaine. Color signifies concentration ranging from 0.1124 
(blue) to 70 (red). Based on the differences between adjacent colors, the range of color 
(blue) is non-steady state. (B) Contour plot of concentration distribution of Tetracaine. 
Color signifies concentration ranging from 27.06 (blue) to 70 (red). Based on the 




Figure 3.4 shows the concentration distribution along with the lipid pathway. The length 
of lipid pathway is 101 µm at ten layers FE model. After 1800s diffusion, concentration 
distribution of Tetracaine decreases with increasing distance and is almost a straight line. 
However, after 1800s, the concentration distribution of Lidocaine does not reach steady 
state.  
3.3 Absorbed Mass 
The SYNERA heating component generates a mild warming that is intended to increase 
the skin temperature from 37 °C to 40 °C so as to enhance the diffusion of the local 
anesthetic agents. However, the permeability is calculated by Equation (1.1), which is 
apparent permeability of diffusants at room temperature (25 °C). Therefore, the 
permeability changes with temperature should be considered.  
  Clinical results show that 1.7 gram Lidocaine and 1.6 gram Tetracaine are 
absorbed by the skin after 30min (1800s) [Highlights of Prescribing Information]. In the 
FE model, the distance of diffusion pathway can be ignored. This is because the diffusion 
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depth will not be considered and the author is only interested in the number of molecules 
absorbed by the skin. Therefore, the time-lag can also be ignored. Equation (2.9) can be 
directly used for analytical results (shown in Table 3.2). The FE results are plotted in Figure 
3.5 and Figure 3.6.   
Table 3.2 Absorbed Mass per Unit Area  
 





FE results 1.14E-3 
Tetracaine 
Analytical results 7.578E-3 
FE results 6.52E-3 
 
 
Figure 3.5 shows the curve of absorbed mass of Lidocaine per unit area. The slope of this 
curve decreases with time since the concentration gradient decreases with processing time. 
The black line corresponds to 1.14E-3 kg/m2 of Lidocaine going into skin after 30 min.  
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Figure 3.6 shows the curve of mass absorbed of Tetracaine per unit area. The slope of this 
curve decreases with time since the concentration gradient decreases with processing time. 
The black line shows 7.578kg/m2 Tetracaine going into the skin after 30 min.  
  In this study, the effects of temperature are not considered since thermal analysis 
has been replaced by mass diffusion analysis. However, based on the results in Table 3.2, 
the absorbed mass of Lidocaine for 10cm2, similar to the size of Synera drug, is 1.14mg 
which is smaller than 1.7mg. This is because the extra temperature from heating layer of 
the Synera patch increases the mobility of Lidocaine particles so as to increase the 
penetration rate of Lidocaine. However, the 7.578mg Tetracaine is absorbed by the skin, 
which is much bigger than clinical experiments. This may be because there is a layer 





The objective of this thesis was to build a transdermal finite element model which can 
estimate results of transdermal diffusion experiments. Since the common transdermal 
experiments needs long time to prepare, by mimicking the brick and mortar structure, a 
successful simulation of the stratum corneum lipid pathway accomplished the objective. 
FE model was used in mechanics and heat flow analysis. A method to use a commercial 
FE package (ANSYS) to solve a real transdermal diffusion problem is presented here. The 
method has been validated by comparing FE model results with results for real local 
transdermal patches for which analytical solutions exist. Although scientists believe that 
percutaneous penetration of polar and ionized compounds occurs not only through the lipid 
pathway route (intercellular) but also via a transcellular route that is through the 
corneocytes [25], the intercellular route is the main pathway for high lipophilic molecules. 
The permeability of the intercellular route can be easily calculated by Potts & Guy equation 
(Equation (1.1)) without experimental data, which correlates the skin permeability to solute 
molecular weight and octanol-water partition coefficient. However, the main disadvantage 
of using Potts & Guy equation is that the relationship between permeability and 
temperature (Equation (2.8)) cannot be represented by FE model. This is because in this 
study, parameters of the thermal transfer were replaced by mass diffusion parameters (Table 
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2.2). The stratum corneum model described here are two dimensional (2-D). Using three 
dimensional (3-D) will be a more realistic approach to represent the stratum corneum 
structure. Advantages of three dimensional model over two dimensional model are 
unknown. This is because although 3-D model uses more elements to increase realism, it 
always repeats same geometric structures of 2-D model. Wang [26] already compared 2-D 
and 3-D SC model topology. The same tortuosities of two models was found so that Wang 
argues that 2-D representation of the stratum corneum is adequate for the purpose of 
transdermal diffusion modeling.  
  For accuracy and realism, the use of a biological image is the best option to 
generate the SC topology, especially to observe the concentration distribution in any 
location and any time [27]. But in this study, good approximate flux and time lag results 
were estimated by a regular brick and mortar geometry. Therefore, regular brick and mortar 
geometry can be used instead of the more complicated but realistic irregular geometry.  
  For reducing computational time of 2-D stratum corneum model, different element 
types were used for different results. The element link 33 was used to replace element plane 
55 for concentration distribution contour-plot. This is because using element link 33 can 
remarkably decrease the amount of elements. But link element can be calculated for flux.  
  The next step in this work is to utilize experimental results, time lags and 
permeability, to evaluate FE results with various sets of diffusivity. The transcellular route 
should be considered in situations when FE model deals with hydrophilic compounds.  
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